A Phase 4, Double-Blind, Multi-Center, Placebo-Controlled, Randomized Withdrawal, Safety and Efficacy Study of SPD489 in Adults Aged 18-55 With Attention-Deficit/Hyperactivity Disorder (ADHD)
收藏DataCite Commons2025-05-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00007904/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The primary objective of this study is to evaluate the maintenance of efficacy, as measured
by Adult ADHD Rating Scale with Prompts (Adult ADHD-RS with prompts) and Clinical Global
Impression - Severity (CGI-S) scores, through a randomized withdrawal design when subjects
with ADHD have been on stable treatment with commercial SPD489 for a minimum of 6 months and
are maintained on their screening dose of commercial SPD489.
提供机构：
Vivli
创建时间：
2022-06-14
